FRE Stock Overview
Engages in the development and commercializing of novel formulations for the uses of povidone iodine in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Firebrick Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.056 |
| 52 Week High | AU$0.11 |
| 52 Week Low | AU$0.045 |
| Beta | 1.61 |
| 1 Month Change | 7.69% |
| 3 Month Change | 0% |
| 1 Year Change | 7.69% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -89.43% |
Recent News & Updates
Recent updates
Here's Why We're Watching Firebrick Pharma's (ASX:FRE) Cash Burn Situation
Aug 14
We Think Firebrick Pharma (ASX:FRE) Needs To Drive Business Growth Carefully
May 02We Think Firebrick Pharma (ASX:FRE) Needs To Drive Business Growth Carefully
Dec 14Companies Like Firebrick Pharma (ASX:FRE) Are In A Position To Invest In Growth
Aug 30Shareholder Returns
| FRE | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 1.8% | -4.9% | -2.7% |
| 1Y | 7.7% | -9.3% | 6.5% |
Return vs Industry: FRE exceeded the Australian Pharmaceuticals industry which returned -9.3% over the past year.
Return vs Market: FRE exceeded the Australian Market which returned 6.5% over the past year.
Price Volatility
| FRE volatility | |
|---|---|
| FRE Average Weekly Movement | 10.5% |
| Pharmaceuticals Industry Average Movement | 10.3% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in AU Market | 16.8% |
| 10% least volatile stocks in AU Market | 3.1% |
Stable Share Price: FRE has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: FRE's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | n/a | Peter Molloy | www.firebrickpharma.com |
Firebrick Pharma Limited engages in the development and commercializing of novel formulations for the uses of povidone iodine in Australia. The company offers broad-spectrum antimicrobial nasal spray for the treatment of common cold under the Nasodine name. It also operates in the United states and Singapore.
Firebrick Pharma Limited Fundamentals Summary
| FRE fundamental statistics | |
|---|---|
| Market cap | AU$11.77m |
| Earnings (TTM) | -AU$1.18m |
| Revenue (TTM) | AU$2.75m |
4.3x
P/S Ratio-10.0x
P/E RatioIs FRE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FRE income statement (TTM) | |
|---|---|
| Revenue | AU$2.75m |
| Cost of Revenue | AU$37.30k |
| Gross Profit | AU$2.71m |
| Other Expenses | AU$3.89m |
| Earnings | -AU$1.18m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0056 |
| Gross Margin | 98.64% |
| Net Profit Margin | -42.75% |
| Debt/Equity Ratio | 0% |
How did FRE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 22:09 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Firebrick Pharma Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|